<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01683253</url>
  </required_header>
  <id_info>
    <org_study_id>SKL004</org_study_id>
    <nct_id>NCT01683253</nct_id>
  </id_info>
  <brief_title>Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa</brief_title>
  <acronym>REIN-PD</acronym>
  <official_title>The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved&#xD;
      and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist&#xD;
      to levodopa/carbidopa in patients with Parkinson's disease who have been treated with&#xD;
      dopaminergic medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  PRIMARY OBJECTIVE To evaluate the improvement of mMIDI(modified version of Minnesota&#xD;
           Impulsive Disorders Interview,Korean version) score from the baseline to 12 weeks or&#xD;
           LOCF(Last Observation Carried Forward)&#xD;
&#xD;
        -  SECONDARY OBJECTIVE i) To evaluate the improvement of neuropsychiatric profiles from the&#xD;
           baseline to 12 weeks or LOCF ii) To evaluate the improvement of UPDRS(Unified&#xD;
           Parkinson's Disease Rating Scale)Score from the baseline to 12 weeks or LOCF&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mMIDI(modified Minnesota Impulsive Disorders Interview)</measure>
    <time_frame>12weeks</time_frame>
    <description>To evaluate the improvement of mMIDI(Korean version) score from the baseline to 12 weeks or LOCF(Last Observation Carried Forward)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the improvement of neuropsychiatric profiles from the baseline to 12 weeks or LOCF&#xD;
* Neuropsychological assessment&#xD;
General cognitive status: K-Minimental status exam(K-MMSE)&#xD;
Psychiatric profile:&#xD;
Neuropsychiatric inventory (K-NPI)&#xD;
Beck depression inventory (BDI)&#xD;
Barratt impulsiveness scale (BIS)&#xD;
Beck anxiety inventory (BAI)&#xD;
State-trait anger expression inventory (STAXI)&#xD;
Obsessive compulsive inventory (OCI)&#xD;
Evaluation of global change:&#xD;
Patient global impression of improvement (PGI-I)&#xD;
Clinical global impression of improvement (CGI-I)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Impulse Control Disorder</condition>
  <arm_group>
    <arm_group_label>Levodopa/Carbidopa(200mg/50mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control A (dopaminergic agonist )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parkinson patients treated with anti-Parkinson drug over 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control B (no drug)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Parkinson diseased patients not treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa(200mg/50mg)</intervention_name>
    <arm_group_label>Levodopa/Carbidopa(200mg/50mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopaminergic Agonists</intervention_name>
    <description>Treated for at least 6 months after diagnosis of Parkinson's Disease.</description>
    <arm_group_label>Control A (dopaminergic agonist )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a diagnosis of idiopathic PD according to United Kingdom Parkinson's&#xD;
             Disease Brain Bank Criteria&#xD;
&#xD;
          -  mMIDI ≥ 3 score with ICD&#xD;
&#xD;
          -  Patients must be on an anti-parkinson treatment at least 6 months before screening.&#xD;
&#xD;
          -  for this protocol, dopamine agonists should be included in his/her anti-parkinson&#xD;
             treatment.&#xD;
&#xD;
          -  30years ≤ patients &lt; 80years of age, male or female&#xD;
&#xD;
          -  patients must give written informed consent before any assessment is performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement of treatment with serious cognitive disorder, behavioral disorder, or&#xD;
             mental illness currently or in the future&#xD;
&#xD;
          -  for the patients ≤ 65years: K-MMSE(korean version of Mini-Mental State Exam) ≤24, or&#xD;
             for the patients ≥ 66years: K-MMSE ≤ 20, or the patients have dementia(incl. early&#xD;
             dementia) even though K-MMSE score is more than 20&#xD;
&#xD;
          -  Requirement of treatment more than 6times per day due to the severe motor fluctuation.&#xD;
&#xD;
          -  Severe dyskinesia&#xD;
&#xD;
          -  DBS(Deep Brain Stimulation)or any other surgical treatment&#xD;
&#xD;
          -  History of melanoma or not-diagnostic skin trouble/skin lesions&#xD;
&#xD;
          -  narrow angle glaucoma&#xD;
&#xD;
          -  clinically serious surgical or medical condition&#xD;
&#xD;
          -  malignant tumor&#xD;
&#xD;
          -  use of other investigational drugs at the time of enrollment within 4weeks&#xD;
&#xD;
          -  pregnant, nursing or lactating women&#xD;
&#xD;
          -  women of child-bearing potential&#xD;
&#xD;
          -  history of hypersensitivity or allergy to levodopa/carbidopa&#xD;
&#xD;
          -  any serious disease according to the investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinwhan Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

